Pretreatment CT Texture Parameters as Predictive Biomarkers of Progression-Free Survival in Follicular Lymphoma Treated with Immunochemotherapy and Rituximab Maintenance.
X-ray computed
follicular lymphoma
positron emission tomography
tomography
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
30 Jun 2023
30 Jun 2023
Historique:
received:
03
05
2023
revised:
20
06
2023
accepted:
26
06
2023
medline:
14
7
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
epublish
Résumé
The purpose of this study was to determine whether texture analysis features present on pretreatment unenhanced computed tomography (CT) images, derived from 18F-fluorodeoxyglucose positron emission/computed tomography (18-FDG PET/CT), can predict progression-free survival (PFS), progression-free survival at 24 months (PFS 24), time to next treatment (TTNT), and overall survival in patients with high-tumor-burden follicular lymphoma treated with immunochemotherapy and rituximab maintenance. Seventy-two patients with follicular lymphoma were retrospectively included. Texture analysis was performed on unenhanced CT images extracted from 18-FDG PET/CT examinations that were obtained within one month before treatment. Skewness at a fine texture scale (SSF = 2) was an independent predictor of PFS (hazard ratio = 3.72 (95% CI: 1.15, 12.11),
Identifiants
pubmed: 37443630
pii: diagnostics13132237
doi: 10.3390/diagnostics13132237
pmc: PMC10340740
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Eur Radiol. 2012 Apr;22(4):796-802
pubmed: 22086561
Eur Radiol. 2019 Jun;29(6):3183-3191
pubmed: 30645669
Eur Radiol. 2017 Mar;27(3):1012-1020
pubmed: 27380902
J Clin Oncol. 2019 Apr 20;37(12):984-991
pubmed: 30811293
Blood. 2008 Dec 15;112(13):4824-31
pubmed: 18799723
Cancer Imaging. 2013 Sep 23;13(3):400-6
pubmed: 24061266
Radiology. 2014 Jan;270(1):141-8
pubmed: 23985274
J Clin Oncol. 2016 Oct 20;34(30):3618-3626
pubmed: 27551111
Leuk Lymphoma. 2017 Jul;58(7):1570-1580
pubmed: 27830968
Blood. 2005 Dec 1;106(12):3725-32
pubmed: 16123223
Diagn Interv Imaging. 2023 Mar;104(3):113-122
pubmed: 36283933
Cancer Imaging. 2013 Mar 26;13:140-9
pubmed: 23545171
Radiology. 2018 Aug;288(2):445-455
pubmed: 29584597
Blood. 2016 Apr 28;127(17):2055-63
pubmed: 26989204
Cancer Imaging. 2016 Apr 11;16:10
pubmed: 27066905
J Clin Oncol. 2015 Aug 10;33(23):2516-22
pubmed: 26124482
J Clin Oncol. 2009 Sep 20;27(27):4555-62
pubmed: 19652063
Radiology. 2013 Jan;266(1):177-84
pubmed: 23151829
Diagn Interv Imaging. 2023 Jan;104(1):24-36
pubmed: 36272931
Blood. 2013 Aug 8;122(6):981-7
pubmed: 23777769
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
J Clin Oncol. 2016 Oct 20;34(30):3591-3594
pubmed: 27601547
Blood. 2004 Sep 1;104(5):1258-65
pubmed: 15126323
J Clin Oncol. 2019 Nov 1;37(31):2815-2824
pubmed: 31339826
Diagn Interv Imaging. 2021 May;102(5):287-295
pubmed: 33419692
Lancet. 2011 Jan 1;377(9759):42-51
pubmed: 21176949
Int J Hematol. 2012 Nov;96(5):544-51
pubmed: 23108535
J Clin Oncol. 2017 Mar 10;35(8):918-919
pubmed: 28029311
Eur Radiol. 2019 Mar;29(3):1231-1239
pubmed: 30159621
CA Cancer J Clin. 2016 Nov 12;66(6):443-459
pubmed: 27618563
Radiographics. 2017 Sep-Oct;37(5):1483-1503
pubmed: 28898189
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Ann Hematol. 2018 Feb;97(2):209-227
pubmed: 29032510
Diagn Interv Imaging. 2022 Feb;103(2):97-102
pubmed: 34666945
Diagn Interv Imaging. 2023 Jan;104(1):1-5
pubmed: 36494290
Adv Exp Med Biol. 2014;772:41-53
pubmed: 24272353
Br J Haematol. 2012 Jan;156(2):225-33
pubmed: 22126847
Radiology. 2013 Dec;269(3):801-9
pubmed: 23912620
Diagn Interv Imaging. 2022 Dec;103(12):571-573
pubmed: 36280585
Am J Hematol. 2016 Nov;91(11):1096-1101
pubmed: 27465588